<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908722</url>
  </required_header>
  <id_info>
    <org_study_id>CR108960</org_study_id>
    <secondary_id>2020-005801-14</secondary_id>
    <secondary_id>VAC31518COV3003</secondary_id>
    <nct_id>NCT04908722</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults</brief_title>
  <official_title>A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune&#xD;
      responses after 6 dose levels of Ad26.COV2.S.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Main Study: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) S Protein Binding Antibodies Concentration Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination</measure>
    <time_frame>28 days after first vaccination (Day 29)</time_frame>
    <description>SARS-CoV-2 S protein binding antibodies concentration measured by ELISA will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Main Study: ELISA Geometric Mean Concentrations (GMCs) 28 Days After First Vaccination</measure>
    <time_frame>28 days after first vaccination (Day 29)</time_frame>
    <description>Non-inferiority (NI) will be assessed in terms of humoral immune response expressed by the GMCs of S-ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Main Study: SARS-CoV-2 S Protein Binding Antibodies Concentration Measured by ELISA 14 Days After Second Vaccination</measure>
    <time_frame>14 days after second vaccination (Day 71)</time_frame>
    <description>SARS-CoV-2 S protein binding antibodies concentration measured by ELISA will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Main Study: ELISA GMCs 14 Days After Second Vaccination</measure>
    <time_frame>14 days after second vaccination (Day 71)</time_frame>
    <description>NI will be assessed in terms of humoral immune response expressed by the GMCs of S-ELISA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Main and Sub Study: SARS-CoV-2 S Protein Binding Antibodies Concentration Measured by ELISA</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>SARS-CoV-2 S protein binding antibodies as assessed by ELISA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main and Sub Study: Antibody Geometric Mean Concentrations (GMCs) as Assessed by S-ELISA</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>Antibody GMCs as assessed by S-ELISA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main and Sub Study: Percentage of Participants Achieving Seroconversion of Serum Antibody Against the SARS-CoV-2 S Protein by S-ELISA</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>Percentage of participants achieving seroconversion of serum antibody against the SARS-CoV-2 S protein by S-ELISA will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main and Sub Study: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination</measure>
    <time_frame>7 days after first vaccination on Day 1 (up to Day 8); 7 days after second vaccination on Day 57 (up to Day 64)</time_frame>
    <description>Solicited local AEs include injection site pain/tenderness, erythema and swelling at the study vaccine injection site and the extent (largest diameter) of any erythema and swelling (using the ruler supplied) will be noted in the participant diary after 7 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main and Sub Study: Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination</measure>
    <time_frame>7 days after first vaccination on Day 1 (up to Day 8); 7 days after second vaccination on Day 57 (up to Day 64)</time_frame>
    <description>Solicited systemic AEs (include body temperature, fatigue, headache, nausea, myalgia) will be noted in the participant diary after 7 days of each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main and Sub Study: Number of Participants with Unsolicited AEs for 28 Days After Each Vaccination</measure>
    <time_frame>28 days after first vaccination on Day 1 (up to Day 29); 28 days after second vaccination on Day 57 (up to Day 85)</time_frame>
    <description>Unsolicited AEs are all AEs for which the participant is not specifically questioned in the participant diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main and Sub Study: Number of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>SAE is any untoward medical occurrence that at any dose may results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main and Sub Study: Number of Participants with Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>Number of participants with AESIs will be reported. Thrombosis with thrombocytopenia syndrome is considered to be an AESI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main and Sub Study: Number of Participants with Medically-Attended Adverse Events (MAAEs)</measure>
    <time_frame>6 months after second vaccination (up to 32 weeks)</time_frame>
    <description>MAAEs are defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits will not be considered medically-attended visits. New onset of chronic diseases will be collected as part of the MAAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main Study: Number of Participants with AEs Leading to Study Discontinuation</measure>
    <time_frame>Up to 60 weeks</time_frame>
    <description>Number of participants with AEs leading to study discontinuation will be reported.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1590</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1: Ad26.COV2.S Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the main study and sub study will receive intramuscular (IM) injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 1 on Days 1 and 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Ad26.COV2.S Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 2 on Days 1 and 57 in the main study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Ad26.COV2.S Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 3 on Days 1 and 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Ad26.COV2.S Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 4 on Days 1 and 57 in the main study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Ad26.COV2.S Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 5 on Days 1 and 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: Ad26.COV2.S Dose Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the main study and sub study will receive IM injections of Ad26.COV2.S as a 2-dose vaccination regimen at dose level 6 on Days 1 and 57.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.COV2.S</intervention_name>
    <description>Participants will receive intramuscular (IM) injections of Ad26.COV2.S.</description>
    <arm_group_label>Group 1: Ad26.COV2.S Dose Level 1</arm_group_label>
    <arm_group_label>Group 2: Ad26.COV2.S Dose Level 2</arm_group_label>
    <arm_group_label>Group 3: Ad26.COV2.S Dose Level 3</arm_group_label>
    <arm_group_label>Group 4: Ad26.COV2.S Dose Level 4</arm_group_label>
    <arm_group_label>Group 5: Ad26.COV2.S Dose Level 5</arm_group_label>
    <arm_group_label>Group 6: Ad26.COV2.S Dose Level 6</arm_group_label>
    <other_name>JNJ-78436735</other_name>
    <other_name>Ad26COVS1</other_name>
    <other_name>VAC31518</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must sign an informed consent form (ICF) indicating that he or she&#xD;
             understands the purpose, procedures and potential risks and benefits of the study, and&#xD;
             is willing to participate in the study&#xD;
&#xD;
          -  Participant must be healthy, in the investigator's clinical judgment, as confirmed by&#xD;
             medical history, physical examination, and vital signs performed at screening.&#xD;
             Participant may have underlying illnesses, as long as the symptoms and signs are&#xD;
             medically controlled and not considered to be comorbidities related to an increased&#xD;
             risk of severe Coronavirus disease 2019 (COVID-19), except for smoking, which is&#xD;
             allowed. If on medication for a condition, the medication dose must have been stable&#xD;
             for at least 12 weeks preceding vaccination and expected to remain stable for the&#xD;
             duration of the study. Participant will be included on the basis of physical&#xD;
             examination, medical history, and vital signs&#xD;
&#xD;
          -  All female participants of childbearing potential must: a) have a negative highly&#xD;
             sensitive urine pregnancy test at screening; b) have a negative highly sensitive urine&#xD;
             pregnancy test immediately prior to each study vaccine administration&#xD;
&#xD;
          -  Participant agrees to not donate bone marrow, blood, and blood products from the first&#xD;
             study vaccine administration until 3 months after receiving the last dose of study&#xD;
             vaccine&#xD;
&#xD;
          -  Participant must be willing to provide verifiable identification, has means to be&#xD;
             contacted and to contact the investigator during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a clinically significant acute illness (this does not include minor&#xD;
             illnesses such as diarrhea or mild upper respiratory tract infection) or temperature&#xD;
             greater than or equal to (&gt;=) 38.0 degree Celsius (C) (100.4 degree Fahrenheit [F])&#xD;
             within 24 hours prior to the planned first dose of study vaccine; randomization at a&#xD;
             later date is permitted at the discretion of the investigator and after consultation&#xD;
             with the sponsor&#xD;
&#xD;
          -  Participant has a known or suspected allergy or history of anaphylaxis or other&#xD;
             serious adverse reactions to vaccines or their excipients (including specifically the&#xD;
             excipients of the study vaccine)&#xD;
&#xD;
          -  Participant received or plans to receive: (a) licensed live attenuated vaccines -&#xD;
             within 28 days before or after planned administration of the first or subsequent study&#xD;
             vaccinations; and (b) other licensed (not live) vaccines - within 14 days before or&#xD;
             after planned administration of the first or subsequent study vaccinations&#xD;
&#xD;
          -  Participant received an investigational drug (including investigational drugs for&#xD;
             prophylaxis of COVID-19) or used an invasive investigational medical device within 30&#xD;
             days or received investigational immunoglobulin (Ig) or monoclonal antibodies within 3&#xD;
             months, or received convalescent serum for COVID-19 treatment within 4 months or&#xD;
             received an investigational vaccine within 6 months before the planned administration&#xD;
             of the first dose of study vaccine or is currently enrolled or plans to participate in&#xD;
             another investigational study during the course of this study&#xD;
&#xD;
          -  Participant previously received a coronavirus vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baptist Health Center for Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ark Clinical Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paradigm Clinical Research Centers, Inc.</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Research Foundation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-6204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Wr-McCr, Llc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ark Clinical Research</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Hallandale Beach</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Health Awareness inc.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Floridian Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33179</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medpharmics, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Trial Management Associates, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc.</name>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <zip>73099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC</name>
      <address>
        <city>Keller</city>
        <state>Texas</state>
        <zip>76248</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Your Health</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas da Universidade Federal De Minas Geraisnas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Belo Horizonte</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UFRR - Universidade Federal de Roraima</name>
      <address>
        <city>Boa Vista</city>
        <zip>69304-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>HMCP - Hospital e Maternidade Celso Pierro - PUC-Campinas</name>
      <address>
        <city>Campinas</city>
        <zip>13060-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Núcleo de Medicina Tropical - Universidade Federal do Ceará</name>
      <address>
        <city>Ceará</city>
        <zip>60430-160</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital São José</name>
      <address>
        <city>Criciúma</city>
        <zip>88801-250</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisas em Moléstias Infecciosas</name>
      <address>
        <city>Natal</city>
        <zip>59025-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Das Clínicas Da Faculdade de Medicina de Ribeirão Preto</name>
      <address>
        <city>Riberao Preto</city>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Geral de Nova Iguacu - HGNI DST/AIDS</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>26030-380</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Referencia E Treinamento Dst/Aids</name>
      <address>
        <city>Sao Paulo</city>
        <zip>02141-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CPQuali Pesquisa Clinica LTDA ME</name>
      <address>
        <city>São Paulo</city>
        <zip>01228-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin-Mitte GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research HamburggmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hannover-Mitte GmbH</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PRATIA Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-796</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Osrodek Badan Klinicznych Wczesnych Faz</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Neutrum Lekarze M.Hlebowicz i Partnerzy spolka partnerska</name>
      <address>
        <city>Gdansk</city>
        <zip>80-462</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Gdanskie Centrum Zdrowia</name>
      <address>
        <city>Gdansk</city>
        <zip>80-542</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Medyk</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Poznan</name>
      <address>
        <city>Skorzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz, Nzoz, Praktyka Grupowa Lekarzy Rodzinnych z Przychodn</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Szpital im. Swietej Jadwigi Slaskiej, Oddział Pediatryczny z Pododdziałem Niemowlęcym</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Wroclawskie Centrum Zdrowia</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-136</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych, Osrodek Badan Wczesnej Fazy</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Synexus Helderberg Clinical Research Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ndlovu Elandsdoorn Site</name>
      <address>
        <city>Dennilton</city>
        <zip>0485</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queenswood Clinical Trial Centre</name>
      <address>
        <city>Gauteng</city>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre for the AIDS Programme of Research in South Africa</name>
      <address>
        <city>KwaZulu-Natal</city>
        <zip>4110</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanza Clinical Research Centre : Mamelodi</name>
      <address>
        <city>Mamelodi East</city>
        <zip>122</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>PHOENIX PHARMA (Pty) Ltd</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre</name>
      <address>
        <city>Soshanguve</city>
        <zip>152</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108960</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

